FDA Priority Review Sends Agios Pharmaceuticals (NASDAQ: AGIO) Stock Price Surging 13.8% As Sickle Cell Drug Gains Momentum
Agios Pharmaceuticals (NASDAQ: AGIO) shares climbed 13.8% during the week through Friday morning, fueled by a significant regulatory development for its lead drug candidate. The Food and Drug…
Read the full articleYou might also wanna read
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week
An accelerated approval for Agios' key drug to treat sickle cell disease appears to be on the cards.
Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)
The company received some good news on its most important drug today.
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
The company recently wowed investors with clinical trial results.
Chip stocks boost global markets ahead of SK Hynix blockbuster US debut
European shares were muted on Friday, with the pan-European STOXX 600 up 0.1%, remaining on track for a weekly loss that could snap a four-
Celltrion's High-Margin Follow-On Products Expand Share in Europe
Celltrion's high-margin follow-on biosimilars are expanding their share across Europe, with Omlyclo reaching 16% and Vegzelma and Yuflyma ho
SK hynix Heads to Nasdaq: Can It Reach Micron-Level Valuation?
SK hynix plans a $28.1 billion Nasdaq ADR listing on the 10th, the largest by a foreign firm, fueling hopes for a Micron-level valuation des
Comments
Sign in to join the conversation.
No comments yet. Be the first.